FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022338332> ?p ?o ?g. }

• W2022338332 endingPage "e103" @default.
• W2022338332 startingPage "e103" @default.
• W2022338332 abstract "Abstract Cancer cells display an increased demand for glucose. Therefore, identifying the specific aspects of glucose metabolism that are involved in the pathogenesis of cancer may uncover novel therapeutic nodes. Recently, there has been a renewed interest in the role of the pentose phosphate pathway in cancer. This metabolic pathway is advantageous for rapidly growing cells because it provides nucleotide precursors and helps regenerate the reducing agent NADPH, which can contribute to reactive oxygen species (ROS) scavenging. Correspondingly, clinical data suggest glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the pentose phosphate pathway, is upregulated in prostate cancer. We hypothesized that androgen receptor (AR) signaling, which plays an essential role in the disease, mediated prostate cancer cell growth in part by increasing flux through the pentose phosphate pathway. Here, we determined that G6PD, NADPH and ribose synthesis were all increased by AR signaling. Further, this process was necessary to modulate ROS levels. Pharmacological or molecular inhibition of G6PD abolished these effects and blocked androgen-mediated cell growth. Mechanistically, regulation of G6PD via AR in both hormone-sensitive and castration-resistant models of prostate cancer was abolished following rapamycin treatment, indicating that AR increased flux through the pentose phosphate pathway by the mammalian target of rapamycin (mTOR)-mediated upregulation of G6PD. Accordingly, in two separate mouse models of Pten deletion/elevated mTOR signaling, Pb-Cre;Pten f/f and K8-CreER T2 ;Pten f/f , G6PD levels correlated with prostate cancer progression in vivo . Importantly, G6PD levels remained high during progression to castration-resistant prostate cancer. Taken together, our data suggest that AR signaling can promote prostate cancer through the upregulation of G6PD and therefore, the flux of sugars through the pentose phosphate pathway. Hence, these findings support a vital role for other metabolic pathways (that is, not glycolysis) in prostate cancer cell growth and maintenance." @default.
• W2022338332 created "2016-06-24" @default.
• W2022338332 creator A5003687822 @default.
• W2022338332 creator A5014680471 @default.
• W2022338332 creator A5016792966 @default.
• W2022338332 creator A5027749729 @default.
• W2022338332 creator A5028628268 @default.
• W2022338332 creator A5041663727 @default.
• W2022338332 creator A5048556795 @default.
• W2022338332 creator A5072423824 @default.
• W2022338332 creator A5079749941 @default.
• W2022338332 date "2014-05-26" @default.
• W2022338332 modified "2023-10-11" @default.
• W2022338332 title "Regulation of the pentose phosphate pathway by an androgen receptor–mTOR-mediated mechanism and its role in prostate cancer cell growth" @default.
• W2022338332 cites W1963502651 @default.
• W2022338332 cites W1963723155 @default.
• W2022338332 cites W1966969388 @default.
• W2022338332 cites W1973121454 @default.
• W2022338332 cites W1982219839 @default.
• W2022338332 cites W1982620126 @default.
• W2022338332 cites W1988500984 @default.
• W2022338332 cites W1989935632 @default.
• W2022338332 cites W1990561391 @default.
• W2022338332 cites W1993350172 @default.
• W2022338332 cites W1998166655 @default.
• W2022338332 cites W2000483762 @default.
• W2022338332 cites W2003866931 @default.
• W2022338332 cites W2003963796 @default.
• W2022338332 cites W2005881694 @default.
• W2022338332 cites W2005920747 @default.
• W2022338332 cites W2008473350 @default.
• W2022338332 cites W2009041102 @default.
• W2022338332 cites W2012019009 @default.
• W2022338332 cites W2016535776 @default.
• W2022338332 cites W2018734911 @default.
• W2022338332 cites W2021181403 @default.
• W2022338332 cites W2021466588 @default.
• W2022338332 cites W2022034132 @default.
• W2022338332 cites W2022101765 @default.
• W2022338332 cites W2024509852 @default.
• W2022338332 cites W2036521855 @default.
• W2022338332 cites W2046100445 @default.
• W2022338332 cites W2046234516 @default.
• W2022338332 cites W2052543023 @default.
• W2022338332 cites W2056040807 @default.
• W2022338332 cites W2072451938 @default.
• W2022338332 cites W2072549244 @default.
• W2022338332 cites W2073332412 @default.
• W2022338332 cites W2073495273 @default.
• W2022338332 cites W2074892828 @default.
• W2022338332 cites W2075914357 @default.
• W2022338332 cites W2085847636 @default.
• W2022338332 cites W2091483394 @default.
• W2022338332 cites W2093922234 @default.
• W2022338332 cites W2095873383 @default.
• W2022338332 cites W2098720660 @default.
• W2022338332 cites W2106400228 @default.
• W2022338332 cites W2107633226 @default.
• W2022338332 cites W2108609254 @default.
• W2022338332 cites W2110103733 @default.
• W2022338332 cites W2113274055 @default.
• W2022338332 cites W2113334939 @default.
• W2022338332 cites W2114704791 @default.
• W2022338332 cites W2115806147 @default.
• W2022338332 cites W2117692326 @default.
• W2022338332 cites W2119621449 @default.
• W2022338332 cites W2127063807 @default.
• W2022338332 cites W2137741805 @default.
• W2022338332 cites W2139677318 @default.
• W2022338332 cites W2157862022 @default.
• W2022338332 cites W2161810908 @default.
• W2022338332 cites W2165161190 @default.
• W2022338332 cites W2166337262 @default.
• W2022338332 cites W2169695895 @default.
• W2022338332 cites W2170240687 @default.
• W2022338332 cites W2170529101 @default.
• W2022338332 cites W2320829700 @default.
• W2022338332 cites W2341758899 @default.
• W2022338332 doi "https://doi.org/10.1038/oncsis.2014.18" @default.
• W2022338332 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4035695" @default.
• W2022338332 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24861463" @default.
• W2022338332 hasPublicationYear "2014" @default.
• W2022338332 type Work @default.
• W2022338332 sameAs 2022338332 @default.
• W2022338332 citedByCount "115" @default.
• W2022338332 countsByYear W20223383322014 @default.
• W2022338332 countsByYear W20223383322015 @default.
• W2022338332 countsByYear W20223383322016 @default.
• W2022338332 countsByYear W20223383322017 @default.
• W2022338332 countsByYear W20223383322018 @default.
• W2022338332 countsByYear W20223383322019 @default.
• W2022338332 countsByYear W20223383322020 @default.
• W2022338332 countsByYear W20223383322021 @default.
• W2022338332 countsByYear W20223383322022 @default.
• W2022338332 countsByYear W20223383322023 @default.
• W2022338332 crossrefType "journal-article" @default.
• W2022338332 hasAuthorship W2022338332A5003687822 @default.
• W2022338332 hasAuthorship W2022338332A5014680471 @default.

• next